Eicosapentaenoic acid-enriched phospholipid ameliorates insulin resistance and lipid metabolism in diet-induced-obese mice

Lipids in Health and Disease

Yuming Wang³  Changhu Xue³  Teruyoshi Yanagita²  Jingfeng Wang³  Qiaoming Lou¹  Chunhua Liu³  Yong Xue³  Xiaofang Liu³ 

[1]Faculty of Life Science and Biotechnology, Ningbo University, No.818 Feng Hua Road, Ningbo, Zhejiang Provence, 315211, PR China

[2]Department of Health and Nutrition Science, Nishikyushu University, Saga, 842-8585, Japan

[3]College of Food Science and Engineering, Ocean University of China, No.5 Yushan Road, Qingdao, Shandong Province, 266003, PR China

关键词: Lipid metabolism;    Insulin resistance;    Obesity;    Metabolic syndrome;    Phospholipid;    Eicosapentaenoic acid;   

Others  :  1160018
DOI  :  10.1186/1476-511X-12-109

 received in 2013-05-08, accepted in 2013-07-19,  发布年份 2013

【 摘 要 】

Background

Over the past two decades, a striking increase in the number of people with metabolic syndrome (MS) has taken place worldwide. With the elevated risk of not only diabetes but also cardiovascular morbidity and mortality, there is urgent need for strategies to prevent this emerging global epidemic. The present study was undertaken to investigate the effects of dietary eicosapentaenoic acid-enriched phospholipid (EPA-PL) on metabolic disorders.

Methods

Male C57BL/6J mice (n = 7) were fed one of the following 4 diets for a period of 4 weeks: 1) a modified AIN-96G diet with 5% corn oil (control diet); 2) a high fat (20%, wt/wt) and high fructose (20%, wt/wt) diet (HF diet); 3) the HF diet containing 1% SOY-PL (SOY-PL diet); 4) the HF diet containing 1% EPA-PL (EPA-PL diet). The oral glucose tolerance test was performed. Plasma TG, TC, glucose, NEFA, insulin, leptin, adiponectin, TNF-α and IL-6 levels were assessed. In addition, hepatic lipid levels, lipogenic, and lipidolytic enzyme activities and gene expressions were evaluated.

Results

Both EPA-PL and SOY-PL significantly inhibited body weight gain and white adipose tissue accumulation, alleviated glucose intolerance, and lowered both serum fasting glucose and NEFA levels substantially. Only EPA-PL significantly reduced serum TNF-α and IL-6 levels, and increased serum adiponectin level. EPA-PL was more effective in reducing hepatic and serum TG and TC levels than SOY-PL. Both EPA-PL and SOY-PL reduced the activities of hepatic lipogenic enzymes, such as FAS and G6PDH, but only EPA-PL significantly increased CPT, peroxisomal β-oxidation enzymes activities and CPT-1a mRNA level. Alterations of hepatic lipogenic gene expressions, such as FAS, G6PDH, ACC, SCD-1 and SREBP-1c were consistent with changes in related enzyme activities.

Conclusions

According to our study, EPA-PL supplementation was efficacious in suppressing body fat accumulation, and alleviating insulin resistance and hepatic steatosis by modulating the secretion of adipocytokines and inflammatory cytokines, suppression of SREBP-1c mediated lipogenesis and enhancement of fatty acid β-oxidation. These results demonstrate that EPA-PL is a novel beneficial food component for the prevention and improvement of metabolic disorders.

【 授权许可】

   
2013 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Van Gaal LF, Mertens IL, De Block CE: Mechanisms linking obesity with cardiovascular disease. Nature 2006, 444:875-880.
• [2]Harris WS: n-3 fatty acids and serum lipoproteins: animal studies. Am J Clin Nutr 1997, 65(5):1611S-1616S.
• [3]Eslick GD, Howe PR, Smith C, Priest R, Bensoussan A: Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol 2009, 136(1):4-16.
• [4]Breslow JL: n-3 fatty acids ans cardiovascular disease. Am J Clin Nutr 2006, 83:1477-1482.
• [5]Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ: Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 2008, 197(1):12-24.
• [6]Cleland LG, James MJ, Proudman SM: The role of fish oils in the treatment of rheumatoid arthritis. Drugs 2003, 63(9):845-853.
• [7]Boudrault C, Bazinet RP, Ma DW: Experimental models and mechanisms underlying the protective effects of n-3 polyunsaturated fatty acids in Alzheimer’s disease. J Nutr Biochem 2009, 20(1):1-10.
• [8]EFSA: Scientific opinion on dietary reference values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA J 2010, 8:1461.
• [9]Cansell M, Nacka F, Combe N: Marine lipid-based liposomes increase in vivo FA bioavailability. Lipids 2003, 38(5):551-559.
• [10]Lemaitre-Delaunay D, Pachiaudi C, Laville M, Pousin J, Armstrong M, Lagarde M: Blood compartmental metabolism of docosahexaenoic acid (DHA) in humans after ingestion of a single dose of [13C]DHA in phosphatidylcholine. J Lipid Res 1999, 40:1867-1874.
• [11]Cohn JS, Wat E, Kamili A, Tandy S: Dietary phospholipids, hepatic lipid metabolism and cardiovascular. Curr Opin Lipidol 2008, 19(3):257-262.
• [12]Morizawa KTY, Tsuchida M, Nakano Y, Hibino H, Tanaka Y: Dietary oils and phospholipids containing n-3 highly unsaturated fatty acids suppress 2,4-dinitro-1- fluorobenzene-induced contact dermatitis in mice. J Jpn Oil Chem Soc 2000, 49(1):59-65.
• [13]Rossmeisl M, Jilkova ZM, Kuda O, Jelenik T, Medrikova D, Stankova B, Kristinsson B, Haraldsson GG, Svensen H, Stoknes I, Sjovall P, Magnusson Y, Balvers MG, Verhoeckx KC, Tvrzicka E, Bryhn M, Kopecky J: Metabolic effects of n-3 PUFA as phospholipids are superior to triglycerides in mice fed a high-fat diet: possible role of endocannabinoids. PLoS One 2012, 7(6):e38834.
• [14]Hiratsuka S, Ishihara K, Kitagawa T, Wada S, Yokogoshi H: Effect of dietary docosahexaenoic acid connecting phospholipids on the lipid peroxidation of the brain in mice. J Nutr Sci Vitaminol (Tokyo) 2008, 54(6):501-506.
• [15]Hiratsuka S, Koizumi K, Ooba T, Yokogoshi H: Effects of dietary docosahexaenoic acid connecting phospholipids on the learning ability and fatty acid composition of the brain. J Nutr Sci Vitaminol (Tokyo) 2009, 55(4):374-380.
• [16]Batetta B, Griinari M, Carta G, Murru E, Ligresti A, Cordeddu L, Giordano E, Sanna F, Bisogno T, Uda S, Collu M, Bruheim I, Di Marzo V, Banni S: Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr 2009, 139(8):1495-1501.
• [17]Bunea R, El Farrah K, Deutsch L: Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia. Altern Med Rev 2004, 9(4):420-428.
• [18]Vigerust NF, Bjorndal B, Bohov P, Brattelid T, Svardal A, Berge RK: Krill oil versus fish oil in modulation of inflammation and lipid metabolism in mice transgenic for TNF-alpha. Eur J Nutrin press
• [19]Shirouchi B, Nagao K, Inoue N, Ohkubo T, Hibino H, Yanagita T: Effect of dietary omega 3 phosphatidylcholine on obesity-related disorders in obese Otsuka Long-Evans Tokushima fatty rats. J Agric Food Chem 2007, 55(17):7170-7176.
• [20]Ulven SM, Kirkhus B, Lamglait A, Basu S, Elind E, Haider T, Berge K, Vik H, Pedersen JI: Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in healthy volunteers. Lipids 2011, 46(1):37-46.
• [21]Maki KC, Reeves MS, Farmer M, Griinari M, Berge K, Vik H, Hubacher R, Rains TM: Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. Nutr Res 2009, 29(9):609-615.
• [22]Hung P, Gu JY, Kaku S, Yunoki S, Ohkura K, Ikeda I, Tachibana H, Sugano M, Yazawa K: Dietary effects of eicosapentaenoic and docosahexaenoic acid esters on lipid metabolism and immune parameters in Sprague–Dawley rats. Biosci Biotechnol Biochem 2000, 64(12):2588-2593.
• [23]Gotoh N, Nagao K, Onoda S, Shirouchi B, Furuya K, Nagai T, Mizobe H, Ichioka K, Watanabe H, Yanagita T, Wada S: Effects of three different highly purified n-3 series highly unsaturated fatty acids on lipid metabolism in C57BL/KsJ-db/db mice. J Agric Food Chem 2009, 57(22):11047-11054.
• [24]Mori TA, Watts GF, Burke V, Hilme E, Puddey IB, Beilin LJ: Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 2000, 102:1264-1269.
• [25]Sierra S, Lara-Villoslada F, Comalada M, Olivares M, Xaus J: Dietary eicosapentaenoic acid and docosahexaenoic acid equally incorporate as docosahexaenoic acid but differ in inflammatory effects. Nutrition 2008, 24(5):245-254.
• [26]Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957, 226(1):497-509.
• [27]Graeve M, Janssen D: Improved separation and quantification of neutral and polar lipid classes by HPLC-ELSD using a monolithic silica phase: application to exceptional marine lipids. J Chromatogr B 2009, 877(20–21):1815-1819.
• [28]Lou QM, Wang YM, Liu XF, Xue CH: Lipid profile and fatty acid compositions in body wall of Apostichopus Japonicus (Selenka). J Food Biochem 2012, 36(3):317-321.
• [29]Bartlett GR: Phosphorous assay in column chromatography. J Biol Chem 1959, 234:466-468.
• [30]Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
• [31]Kelley DS, Nelson GJ, Hunt JE: Effect of prior nutritional status on the activity of lipogenic enzymes in primary monolayer cultures of rat hepatocytes. Biochem J 1986, 235(1):87-90.
• [32]Kelly DS, Kletzien RF: Ethanol modulation of the hormonal and nutritional regulation of glucose 6-phosphate dehydrogenase activity in primary cultures of rat hepatocytes. Biochem J 1984, 217(2):543-549.
• [33]Ochoa S: Malic enzyme. In Methods in Enzymology. Volume 1. Edited by Colowick SP, Kaplan NO. New York, NY: Academic Press; 1955::739-753.
• [34]Markwell MA, McGroarty EJ, Bieber LL, Tolbert NE: The subcellular distribution of carnitine acyltransferase in mammalian liver and kidney A new peroxisomal enzyme. J Biol Chem 1973, 248:3426-3432.
• [35]Lazarow PB: Assay of Peroxisomal β-oxidation of fatty acids. In Methods in Enzymology. Edited by Lowenstein JM. New York, NY: Academic Press; 1981:315-319.
• [36]Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
• [37]Frayn KN: Insulin resistance and lipid metabolism. Curr Opin Lipidol 1993, 4(3):197-204.
• [38]Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD: Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988, 37(8):1020-1024.
• [39]Ouchi N, Parker JL, Lugus JJ, Walsh K: Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011, 11(2):85-97.
• [40]Ohashi K, Ouchi N, Matsuzawa Y: Anti-inflammatory and anti-atherogenic properties of adiponectin. Biochimie 2012, 94(10):2137-2142.
• [41]Tandy S, Chung RWS, Wat E, Kamili A, Berge K, Griinari M, Cohn JS: Dietary krill oil supplementation reduces hepatic steatosis, glycemia, and hypercholesterolemia in high-fat-fed mice. J Agric Food Chem 2009, 57(19):9339-9345.
• [42]Blundell JE, Gillett A: Control of food intake in the obese. Obes Res 2001, 9(S11):263S-270S.
• [43]James MJ, Gibson RA, Cleland LG: Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000, 71(1):343S-348S.
• [44]Krebs JD, Browning LM, McLean NK, Rothwell JL, Mishra GD, Moore CS, Jebb SA: Additive benefits of long chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinemic women. Int J Obes (Lond) 2006, 30:1535-1544.
• [45]Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Hwang BS, Glaser R: Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: a randomized controlled trial. Brain Behav Immun 2012, 26(6):988-995.
• [46]Jump DB, Botolin D, Wang Y, Xu J, Christian B, Demeure O: Fatty acid regulation of hepatic gene transcription. J Nutr 2005, 135(11):2503-2506.
• [47]Froyland L, Vaagenes H, Asiedu DK, Garras A, Lie O, Berge RK: Chronic administration of eicosapentaenoic acid and docosahexaenoic acid as ethyl ester reduced plasma cholesterol and changed the fatty acid composition in rat blood and organs. Lipids 1996, 31(2):169-178.
• [48]Polichetti E, Janisson A, de la Porte PL, Portugal H, Leonardi J, Luna A, La Droitte P, Chanussot F: Dietary polyenylphosphatidylcholine decreases cholesterolemia in hypercholesterolemic rabbits: role of the hepato-biliary axis. Life Sci 2000, 67(21):2563-2576.